phenytoin has been researched along with betadex in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eto, S; Noda, A; Noda, H | 1 |
| Hegde, RP; Rhodes, CT | 1 |
| Narisawa, S; Stella, VJ | 1 |
| McDonald, C; Muzumdar, PP | 1 |
| Iwaki, M; Ogiso, T; Tanino, T | 1 |
| Bhardwaj, R; Blanchard, J; Dorr, RT; Ugwu, SO | 1 |
| Yao, TW; Zeng, S | 1 |
| Asakawa, N; Ishihama, Y; Miwa, T | 1 |
| Chen, J; Hage, DS; Ohnmacht, CM | 1 |
| Jouyban, A; Jouyban-Gharamaleki, V; Karimzadeh, Z; Khajir, S; Khoubnasabjafari, M; Rahimpour, E | 1 |
10 other study(ies) available for phenytoin and betadex
| Article | Year |
|---|---|
Chiral separation of barbiturates and hydantoins by reversed-phase high-performance liquid chromatography using a 25 or 50 mm short ODS cartridge column via beta-cyclodextrin inclusion complexes.
Topics: Barbiturates; beta-Cyclodextrins; Chromatography, High Pressure Liquid; Cyclodextrins; Humans; Hydantoins; Mephobarbital; Phenytoin; Stereoisomerism | 1992 |
Preparation of a phenytoin beta-cyclodextrin complex and evaluation of a suspension and a tablet dosage form prepared from the complex.
Topics: beta-Cyclodextrins; Biological Availability; Cyclodextrins; Dextrins; Drug Combinations; Humans; Phenytoin; Starch; Tablets | 1985 |
Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD.
Topics: beta-Cyclodextrins; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Cyclodextrins; Drug Stability; Hydrogen-Ion Concentration; Kinetics; Phenytoin; Prodrugs; Solubility; Spectrophotometry, Ultraviolet; Temperature | 1998 |
Prevention of precipitation of phenytoin in an infusion fluid by hydroxypropyl beta-cyclodextrin.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Chemical Precipitation; Cyclodextrins; Hydrogen-Ion Concentration; In Vitro Techniques; Infusions, Parenteral; Phenytoin; Solubility | 1998 |
Effect of sugar-modified beta-cyclodextrins on dissolution and absorption characteristics of phenytoin.
Topics: Animals; beta-Cyclodextrins; Cyclodextrins; Drug Interactions; Glucose; Intestinal Mucosa; Intestines; Male; Maltose; Membrane Proteins; Permeability; Phenolsulfonphthalein; Phenytoin; Phospholipids; Powders; Rats; Rats, Wistar; Solubility; X-Ray Diffraction | 1999 |
Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-beta-cyclodextrin.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Chemical Precipitation; Chemistry, Pharmaceutical; Cyclodextrins; Female; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Phenytoin; Skin | 2000 |
Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives.
Topics: Animals; beta-Cyclodextrins; Chromatography, High Pressure Liquid; Cyclodextrins; Male; Microsomes, Liver; Phenytoin; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2001 |
Drug-plasma protein binding assay by electrokinetic chromatography-frontal analysis.
Topics: beta-Cyclodextrins; Blood Proteins; Chromatography, Micellar Electrokinetic Capillary; Cyclodextrins; Diclofenac; Electrophoresis, Capillary; Humans; Ketoprofen; Pharmaceutical Preparations; Phenylbutazone; Phenytoin; Serum Albumin; Sulfathiazole; Sulfathiazoles; Warfarin | 2002 |
Characterization of drug interactions with soluble beta-cyclodextrin by high-performance affinity chromatography.
Topics: beta-Cyclodextrins; Chromatography, Affinity; Chromatography, High Pressure Liquid; Phenytoin; Tamoxifen | 2004 |
A Rayleigh light scattering technique based on β- cyclodextrin modified gold nanoparticles for phenytoin determination in exhaled breath condensate.
Topics: beta-Cyclodextrins; Gold; Humans; Metal Nanoparticles; Phenytoin | 2023 |